All In Biotech

Drug Trial Radar · NCT04924101

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

122

Actual

Start

Jul 15, 2021

Primary completion

Jun 23, 2025

Study completion Jun 23, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

Conditions

  • Small Cell Lung Cancer

Interventions

  • PembrolizumabBiological

    IV infusion

  • MK-4830Biological

    IV infusion

  • BoserolimabBiological

    IV infusion

  • LenvatinibDrug

    Oral capsule

  • EtoposideDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 43 months
  2. Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1Time frame: At 6 months

Locations

49 sites in 11 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0102)

    Gilbert, Arizona

  • University of Colorado Anschutz Medical Campus ( Site 0104)

    Aurora, Colorado

  • Georgia Cancer Specialists ( Site 0106)

    Atlanta, Georgia

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0130)

    Fort Wayne, Indiana

  • Baptist Health Lexington-Research ( Site 0108)

    Lexington, Kentucky

  • MFSMC-HJWCI-Oncology Research ( Site 0128)

    Baltimore, Maryland

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122)

    Omaha, Nebraska

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129)

    Omaha, Nebraska

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114)

    Mineola, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0115)

    New York, New York

  • Cleveland Clinic-Taussig Cancer Center ( Site 0116)

    Cleveland, Ohio

  • UPMC Hillman Cancer Center ( Site 0127)

    Pittsburgh, Pennsylvania

  • St Francis Cancer Center-Research Office ( Site 0117)

    Greenville, South Carolina

  • Virginia Cancer Institute ( Site 0119)

    Richmond, Virginia

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2100)

    Vienna, Austria

  • Klinik Penzing-2. Lungenabteilung ( Site 2101)

    Vienna, State of Vienna, Austria

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2003)

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2005)

    Kingston, Ontario, Canada

  • St. Marys Hospital Center ( Site 2000)

    Montreal, Quebec, Canada

  • Semmelweis University-Pulmonológiai Klinika ( Site 2802)

    Budapest, Hungary

  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2800)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 2806)

    Budapest, Pest County, Hungary

  • Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 2801)

    Törökbálint, Pest County, Hungary

  • Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 2805)

    Zalaegerszeg, Zala County, Hungary

  • Rambam Health Care Campus-Oncology ( Site 2600)

    Haifa, Israel

  • Shaare Zedek Medical Center ( Site 2602)

    Jerusalem, Israel

  • Meir Medical Center ( Site 2601)

    Kfar Saba, Israel

  • Rabin Medical Center-Oncology ( Site 2604)

    Petah Tikva, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 2603)

    Ramat Gan, Israel

  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 2304)

    Milan, Italy

  • Ospedale San Raffaele-Oncologia Medica ( Site 2303)

    Milan, Lombardy, Italy

  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 2300)

    Siena, Tuscany, Italy

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier

    Warsaw, Masovian Voivodeship, Poland

  • Samodzielny Publiczny Zespó Grulicy i Chorób Puc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemi

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 2704)

    Saint Petersburg, Russia

  • Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 2708)

    Krasnoyarsk, Krasnoyarsk Krai, Russia

  • GBUZ "SPb CRPCstmc(o)" ( Site 2705)

    Saint Petersburg, Sankt-Peterburg, Russia

  • N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S

    Saint Petersburg, Sankt-Peterburg, Russia

  • Seoul National University Hospital ( Site 1101)

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1105)

    Seoul, South Korea

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.